Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial

Crystal M. Cooper a, Cherise R. Chin Fatt a, Manish Jha a, Gregory A. Fonzo b,c,d, Bruce D. Grannemann a, Thomas Carmody a, Aasia Ali a, Sina Aslan a,e, Jorge R.C. Almeida i, Thilo Deckersbach e, Maurizio Favag, Benji T. Kuriana, Patrick J. McGrath h, Melvin McInnis l, Ramin V. Parsey j, Myrna Weissman h, Mary L. Phillips k, Hanzhang Lu a,l, Amit Etkin b,c,d, Madhukar H. Trivedi i,*

a Department of Psychiatry, University of Texas Southwestern Medical Center, United States of America
b Department of Psychiatry and behavioural Sciences, Stanford University School of Medicine, United States of America
c Stanford Neurosciences Institute, Stanford University, United States of America
d Department of Psychiatry, University of Texas Austin, United States of America
e Advance MRI, LLC, United States of America
f Stanford Neuroscience Institute, Stanford University, United States of America
g Mental Illness, Research, Education, and Clinical Center (MIRECC), Veterans Affairs Palo Alto Healthcare System, United States of America
h Department of Psychiatry, Columbia University, New York State Psychiatric Institute, United States of America
i Department of Psychiatry, University of Michigan School of Medicine, United States of America
j Departments of Psychiatry, Stony Brook University, United States of America
k Department of Psychiatry, University of Pittsburgh School of Medicine, United States of America
l Department of Radiology, Johns Hopkins University, United States of America

A R T I C L E  I N F O

Article history:
Received 30 November 2018
Received in revised form 10 April 2019
Accepted 11 April 2019
Available online 18 May 2019

A B S T R A C T

Background: Major Depressive Disorder (MDD) has been associated with brain-related changes. However, biomarkers have yet to be defined that could “accurately” identify antidepressant-responsive patterns and reduce the trial-and-error process in treatment selection. Cerebral blood perfusion, as measured by Arterial Spin Labeling (ASL), has been used to understand resting-state brain function, detect abnormalities in MDD, and could serve as a marker for treatment selection. As part of a larger trial to identify predictors of treatment outcome, the current investigation aimed to identify perfusion predictors of treatment response in MDD.

Methods: For this secondary analysis, participants include 231 individuals with MDD from the EMBARC study, a randomised, placebo-controlled trial investigating clinical, behavioural, and biological predictors of antidepressant response. Participants received sertraline (n = 114) or placebo (n = 117) and response was monitored for 8 weeks. Pre-treatment neuroimaging was completed, including ASL. A whole-brain, voxel-wise linear mixed-effects model was conducted to identify brain regions in which perfusion levels differentially predict (moderate) treatment response. Clinical effectiveness of perfusion moderators was investigated by composite moderator analysis and remission rates. Composite moderator analysis combined the effect of individual perfusion moderators and identified which contribute to sertraline or placebo as the “preferred” treatment. Remission rates were calculated for participants “accurately” treated based on the composite moderator (lucky) versus “inaccurately” treated (unlucky).

Findings: Perfusion levels in multiple brain regions differentially predicted improvement with sertraline over placebo. Of these regions, perfusion in the putamen and anterior insula, inferior temporal gyrus, fusiform, parahippocampus, inferior parietal lobule, and orbital frontal gyrus contributed to sertraline response. Remission rates increased from 37% for all those who received sertraline to 53% for those who were lucky to have received it and sertraline was preferred treatment.

Interpretation: This large study showed that perfusion patterns in brain regions involved with reward, salience, affective, and default mode processing moderate treatment response favouring sertraline over placebo. Accurately matching patients with defined perfusion patterns could significantly increase remission rates.

Funding: National Institute of Mental Health, the Hersh Foundation, and the Center for Depression Research and Clinical Care, Peter O’Donnell Brain Institute at UT Southwestern Medical Center.

Trial Registration.

Interpretation: Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMARC) Registration Number: NCT01407094 (https://clinicaltrials.gov/ct2/show/NCT01407094).

© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author at: Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9119, United States of America.
E-mail address: Madhukar.Trivedi@utsouthwestern.edu (M.H. Trivedi).

https://doi.org/10.1016/j.eclinm.2019.04.007
2589-5370/© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Major Depressive Disorder (MDD) is stated to be the leading cause of disability worldwide by the World Health Organization. With remission rates for MDD remaining low, roughly 30%, change is needed to improve outcomes [1]. While MDD is associated with brain-related changes, such as positron emission tomography, providing information on oxygen and nutrient delivery to brain tissue, the potential for other techniques, such as Arterial Spin Labeling (ASL), to improve treatment outcomes remains elusive [2]. The current trial-and-error treatment paradigm results in mismatched treatment selection, thereby delaying the identification of the most appropriate, effective treatments for an individual [3,4]. Magnetic resonance neuroimaging has shown promising results in MDD and yet, brain imaging-based treatments have not been established, especially through placebo-controlled trials [5]. Of the modalities to assess brain function, Arterial Spin Labeling (ASL) is a short, noninvasive neuroimaging technique that reliably measures cerebral blood flow (CBF; perfusion) using a magnetic pulse, opposed to a radioligand, to label blood as it perfuses through the brain to provide oxygen and other nutrients to tissue. This generates a quantifiable measure of perfusion without radiation exposure that can be compared within and across individuals to identify brain function associated with neuropsychiatric disorders and their treatment [6,7].

In recent work, both reliability of cerebral blood perfusion and its potential as a disease-state marker have been investigated. Perfusion has been observed to be reliable in healthy controls across time and in detecting abnormalities in MDD participants as compared to healthy controls [8,9]. Differences in perfusion have been identified between MDD participants and healthy controls in some but not all studies [10–13]. Perfusion abnormalities have been detected in the temporal, frontal, cingulate, and limbic regions [10–12]. Differences in perfusion in the anterior cingulate cortex have also accurately distinguished unipolar from bipolar depression [13]. Recent studies suggest that pre-treatment perfusion can predict antidepressant treatment outcomes. One study compared baseline perfusion in responders and nonresponders to repetitive transcranial magnetic stimulation (TMS) in 13 MDD patients [14]. Baseline perfusion in the left dorsolateral prefrontal cortex was greater in TMS responders, whereas baseline perfusion in the left medial frontal cortex was greater in nonresponders. Another study observed some initial perfusion differences in MDD at baseline compared to healthy controls to normalise after 6 weeks of antidepressant treatment [15]. However, the small samples in these studies and lack of placebo control are significant limitations, hindering the ability to identify moderators of treatment outcome that could be applied clinically.

The current study is a secondary analysis to investigate perfusion moderators of treatment response and their clinical effectiveness from the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study [3]. Unlike predictors (non-specific variables associated with outcome to any treatment), moderators are pre-treatment variables associated with differential treatment outcome to provide information for patient-treatment matching. Relative CBF, a normalised measure of perfusion (nCBF), was evaluated as a potential moderator of antidepressant response in MDD using a whole-brain, voxel-wise, linear mixed-effects model. We predicted that perfusion moderators would be observed in brain regions across networks, those involved in resting-state brain function (default mode) as well as those involved in emotion, reward, and salience processing (e.g., prefrontal, insula, and cingulate cortices; see review on multi-modal imaging and these pathophysiologic processes in MDD [5]). Clinical effectiveness of the perfusion moderators was then evaluated using a composite moderator analysis and remission rates. We predicted perfusion contributors to optimal treatment assignment would increase remission rates for those that received their perfusion-matched treatment. Our model and sample size allow for an unbiased, exploratory approach to identify moderators and their clinical effectiveness.

2. Methods

2.1. Design and Overview

The EMBARC trial aims to identify clinical, behavioural, and biological moderators of antidepressant response in MDD in order to develop a
differential Treatment Response Index of multiple biosignatures. MDD participants were scanned using MRI, including a resting ASL sequence, before treatment initiation and one-week after starting treatment, to detect any early signals of response in the brain. Treatment response was measured for 8 weeks for Phase-1 and an additional 8 weeks for Phase-2, which involved maintenance treatment for responders and a cross-over for nonresponders to alternate treatment. The 17-item Hamilton Depression Rating Scale (HAMD17) was used to track response at baseline and weeks 1, 2, 3, 4, 6, 8 after starting treatment for Phase-1. For the full design and rationale with measures and descriptions, see the Trivedi et al. [3]. The study was approved by the Institutional Review Board at each participating site: Columbia University (CU), Massachusetts General Hospital (MG), University of Michigan (UM), and the University of Texas Southwestern Medical Center (TX).

2.2. Participants

Of the 296 participants included in the EMBARC trial, 231 individuals completed the baseline ASL scan, had usable data that passed quality control, had at least one follow-up visit, and constitute the intent-to-treat analytic sample in this secondary report (Fig. 1). MDD participants were diagnosed using the Structural Clinical Interview for DSM-IV. Participants were 18–65 years old, fluent in English, and had chronic, early-onset MDD (first major depressive episode prior to age 30). MDD participants were excluded if they scored < 14 on the Quick Inventory of Depressive Symptomatology–Self Report, if any other mental disorder was primary to MDD (e.g., Generalized Anxiety Disorder), if they had a lifetime history of a psychotic or bipolar disorder, had a substance abuse disorder within six months (except for nicotine dependence), or had the presence of a medical condition that would compromise

![EMBARC CONSORT Flow Diagram](https://example.com/EMBARC_Flow_Diagram.png)

**Fig. 1.** EMBARC CONSORT Flow Diagram. For this analysis patients were included (1) regardless of their HAMD17 score, (2) had relative cerebral blood flow scans pass quality control, and (3) had at least one follow up visit.
MDD-specific findings. General MRI exclusion criteria were implemented. See Table 1 for demographics. All participants signed informed consent.

2.3. Data Acquisition and Imaging Parameters

EMBARC MRI data were collected at four sites (CU, MG, TX, UM). All ASL sequences were acquired using 3T scanners. Each implemented a 2D-EPI, resting-state, pseudo-continuous ASL (pCASL) technique that was optimized for each scanner while maintaining similar parameters. Generally, pCASL parameters consisted of a 1516 ms labelling duration, 1500 ms post-labeling delay, 4460 ms/17 ms TR/TE, 3.44 × 3.44 × 5 mm in-plane resolution, multi-slice acquisition in ascending order, 29 slices covering the whole brain, 35 pairs, 220 × 220 mm FOV, 64 × 64 matrix, 90° excitation flip angle, with scan duration of approximately 5 min. For further details on the pCASL sequence, refer to Almeida et al. [9]. These imaging parameters are comparable and consistent with recommendations from a recent consensus paper [7]. T1-weighted, high-resolution, structural-3D sagittal images were acquired in the same session.

2.4. Data Processing and Statistical Analysis

2.4.1. Relative Cerebral Blood Flow

Of the 231 participants with usable ASL scans and follow-up data, 114 MDD participants were randomised under double-masked conditions to receive sertraline and 117 to receive placebo. We implemented nCBF to identify perfusion moderators of antidepressant treatment response. Each participant’s nCBF is their relative measure of perfusion, i.e., normalisation of their absolute CBF (aCBF), which divides the aCBF of each voxel by the whole-brain averaged aCBF. nCBF’s normalisation process is useful to decrease intra- and inter-subject variations as well as some cross-site scanner differences, which assists in controlling for basic individual differences that may not be disease-specific. nCBF has high test–retest reliability, as does aCBF (e.g., EMBARC healthy control CBF across time [10]), but has greater sensitivity and reliability in detecting differences in perfusion between groups when compared to aCBF [16].

2.4.2. Image Processing

The ASL data were preprocessed and analysed with SPM8 (Wellcome Department of Cognitive Neurology, UK) in Matlab (MathWorks, Natick, MA). The processing pipeline included: 1) realignment of the ASL time-series to the first image to correct for head motion; 2) generation of perfusion-weighted image series by pairwise subtraction of the label and control images; 3) conversion to aCBF image series based on a single-compartment ASL perfusion model; 4) generation of a mean CBF image for each participant; 5) co-registration of the mean image with the anatomical image; 6) normalisation to the MNI template; 7) resampling of CBF image to 2 × 2 × 2 mm and smoothed with full-width at half-maximum 8 mm kernel; and 8) extracting the nCBF image by dividing out the aCBF global individual mean from each aCBF voxel.2

2.4.3. Moderator Analysis

An exploratory whole-brain, voxel-wise, linear mixed-effects model was conducted to identify moderators of treatment response. The full model conformed to a moderator definition based on interaction effects by Kraemer et al. [17] and was implemented in R. Moderators were identified by a significant treatment (sertraline, placebo) by Time (Weeks 0–8) by nCBF value (voxel-wise correction false discovery rate p < 0.05) interaction controlling for Site (CU, MG, TX, UM) with HAMD17 as the dependent measure (see list of model terms in Supplemental Table 1). Baseline HAMD17 was included as a dependent variable and the group main effect was excluded to ensure equality between groups in HAMD17 at baseline. A significant three-way interaction suggests perfusion in that brain region (nCBF moderator) predicted differential rate of change in HAMD17 with sertraline vs placebo. All nCBF moderators (112 clusters) are presented in Fig. 2. For interpretation, only clusters of >100 voxels for the moderator effect (Treatment × Time × nCBF interaction; 30 clusters) are discussed based on prior ASL work and clinical applicability [16]. For additional details on software, related packages, atlas and coordinate system used, see Supplemental Methods.

2.4.4. Clinical Effectiveness

Combining individual moderators to form a composite moderator provides a comprehensive evaluation and can result in a clinically usable prediction of individual response to a specific treatment in order to determine which treatment will have greatest benefit [18]. The 30 clusters containing >100 voxels comprised the individual perfusion moderators. They were combined into a composite moderator (a weighted sum of the individual moderators as described by Kraemer) [18] to determine which participants would benefit more from sertraline vs placebo. Benefit was defined by the change in depression severity over time expressed as a slope [rate of change in HAMD17 per week]. Slopes were derived from a mixed-effects model corrected for site and computed separately for each treatment arm as described in Petkova et al. [19]. A negative slope indicates improvement. Participants were assigned to a preferred treatment based on the relationship between the composite moderator and the slope for sertraline and placebo groups presented in Fig. 3. Those below the crossover point of the two lines benefit more from sertraline (i.e., assigned sertraline as their perfusion-based, statistically-preferred treatment). Those above that point benefit more from placebo (i.e., assigned placebo as their

---

1. Presence of a neurological condition requiring an anticonvulsant; a medical condition not stable with medication, required hospitalisation or deemed clinically relevant by the investigators; or any abnormal laboratory results the site principal investigator considered clinically significant
2. aCBF means were confirmed to be equivalent between the SERT (M = 42.50; SE = 0.96) and placebo (M = 41.08; SE = 0.94) groups, t = 1.06; p = 0.29.

---

Table 1

Demographic and clinical characteristics for the sertraline and placebo groups.

|          | Sertraline | Placebo | n | % | n | % |
|----------|------------|---------|---|---|---|---|
| Gender   |            |         |   |   |   |   |
| Male     | 35         | 30.70%  | 41 | 35.04% |
| Female   | 79         | 69.30%  | 76 | 64.96% |
| Race     |            |         |   |   |   |   |
| White    | 74         | 64.91%  | 81 | 69.23% |
| African American | 26 | 22.81% | 18 | 15.38% |
| Asian    | 5          | 4.39%   | 10 | 8.55%  |
| Other    | 9          | 7.89%   | 8  | 6.84%  |
| Employment status | | | | | |
| Employed | 63         | 57.27%  | 68 | 59.65% |
| Unemployed | 47       | 42.73%  | 46 | 40.35% |
| Mean     | 37.65      | 13.71   | 36.58 | 12.33 |
| Age      | 46.07      | 74.76   | 46.06 | 76.16 |
| Duration of current episode (months) | 15.82 | 30.02 | 14.61 | 25.82 |
| Number of MDE | 18.72 | 4.57 | 18.98 | 4.31 |
| STAI (Pre-scan) | 48.27 | 11.99 | 47.32 | 11.28 |
| SHAPS    | 5.79       | 3.49    | 5.48 | 3.62 |

Note: Major Depressive Disorder (MDD); Standard Error (SE); Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR); Hamilton Scale for Depression (HAMD17); Major Depressive Episode (MDE); State–Trait Anxiety Inventory (STA); Snaith-Hamilton Pleasure Scale (SHAPS). For number of MDE: Number with too many to count = 1 (7 placebo, 9 sertraline); Number with missing data = 7 (4 placebo, 3 sertraline).
perfusion-based, statistically-preferred treatment). Remission rates and slopes were calculated for lucky (those who were randomised to their perfusion-based, statistically-preferred treatment) and unlucky (those who were randomised to their perfusion-based, statistically-not-preferred treatment) participants as identified by the composite moderator [20]. A participant was defined to be in remission if a HAMD17 score of 7 or less was achieved by the last available acute phase visit. An effect size [18] was computed for the composite moderator, which is scaled from 0 to 1. Using the composite moderator, 48% of participants were identified to benefit more from sertraline and 52% to benefit more from placebo resulting in equivalent assignment.

2.5. Role of Funding Source

The study sponsor approved the overall trial design, study execution, and data collection, which was coordinated by the corresponding author. The study sponsor had no role in data analysis, data interpretation, or writing of the data in the current manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

3. Results

3.1. Perfusion Moderators

The whole-brain voxel-wise linear mixed-effects model revealed 112 statistically significant moderators of treatment outcome (Treatment × Time × nCBF interaction) with 30 clusters containing >100 voxels. These moderators are discussed below by their treatment contribution identified by the combined moderator. Brain regions where perfusion moderated treatment outcome are provided in Table 2. See Fig. 2 and Supplemental Table 2 for detailed cluster information for all significant moderators.

3.2. Clinical Effectiveness

For all participants included in the moderator analyses, 35% (81/231) achieved remission and 65% (150/231) did not achieve remission as the overall treatment outcome. Of the MDD participants that received sertraline, 37% (42/114) achieved remission, and 33% (39/117) of the MDD participants that received placebo achieved remission. To assess the clinical significance of the perfusion moderators, overall treatment efficacy was evaluated by comparing remission rates and slopes of those who either received, lucky, or did not receive, unlucky, their “preferred” treatment according to the composite perfusion moderator. Lucky and unlucky participants were identified by each treatment arm. For both sertraline and placebo treatment, the lucky group demonstrated higher average remission rates as compared to the unlucky group (for sertraline, 53% vs 24%; for placebo, 49% vs 18%; respectively; Fig. 2) and more negative slopes indicating a faster rate of improvement (for sertraline, −1.289 (0.38) vs −0.931 (0.45); for placebo, −1.335 (0.40) vs −1.000 (0.42), respectively). The combined moderator produced an effect size of 0.557.

3.2.1. Sertraline Moderators

Sertraline moderators are regions where perfusion levels contribute to assignment to the sertraline group, i.e., sertraline should be observed as having greater improvement (decrease) in depression severity over the placebo group. This is revealed by negative weights in the composite moderator (−0.007 to −0.240; Table 2). Regions observed include those involved in affective and default mode networks. From highest to lowest contribution, these included: the right putamen (and anterior insula); left inferior temporal gyrus; right fusiform; right inferior (or bital) frontal gyrus; left parahippocampal gyrus; left inferior parietal lobule (the supramarginal gyrus); left fusiform gyrus; bilateral pons;
right precuneus; left inferior parietal lobule (supramarginal and angular gyri); left superior temporal gyrus; left superior temporal gyrus (extending to insula); and the right calcarine cortex.

3.2.2. Placebo Moderators

Placebo moderators are regions where perfusion levels contribute to assignment to the placebo group, i.e., placebo should be observed as having greater improvement (decrease) in depression severity for placebo relative to sertraline. This is revealed by positive weights in composite moderator (0.002–0.136; Table 2). Regions observed include those involved in cognitive control and default mode networks (Table 2). From highest to lowest contribution, these included: the right posterior insula; left midbrain; right hippocampus; right inferior (orbital) frontal; right middle and inferior frontal gyri (including the dorsolateral prefrontal cortex); left precentral gyrus; left inferior (orbital) frontal; left middle temporal gyrus; right caudate; left cerebellum; right middle, superior, and inferior frontal gyri (and dorsolateral and frontopolar prefrontal cortices); left middle frontal gyrus (and dorsolateral prefrontal cortex); right middle temporal gyrus; left cuneus; left cingulate (ventral and dorsal anterior portions); left fusiform gyrus (and lingual gyrus); and the left inferior frontal gyrus (triangularis).

4. Discussion

In this large placebo-controlled study, we identified perfusion moderators of treatment outcome involved in functional networks, i.e., default mode, cognitive control, reward, salience, and affective processing, known to be disrupted in MDD [3]. Particularly, it was perfusion in regions involved in reward, salience, affective and default mode processing that were identified as sertraline moderators. Conversely, perfusion in regions involved in cognitive control and default mode processing were identified as placebo moderators.

Perfusion in the putamen and anterior insula, inferior temporal gyrus, fusiform, parahippocampus, inferior parietal lobule, and orbital frontal gyrus contributed the most to assignment of sertraline as the preferred treatment, showing a faster rate of improvement and increasing remission status from 37% for all those who received sertraline to 53% for those that were assigned sertraline and were *lucky* to have received it.

Perfusion in the posterior insula, midbrain, hippocampus, orbital frontal gyrus, dorsolateral prefrontal cortex, precentral gyrus, caudate, and middle temporal gyrus contributed to assignment to placebo as the preferred treatment, showing a faster rate of improvement and increasing remission status from 33% for all those who received placebo to 49% for the *lucky* group. These results are in line with prior perfusion work (albeit not placebo-controlled) but are the first to identify moderators of treatment response (differential outcome for sertraline vs placebo) [14,15,21].

The majority of regions where perfusion contributed to sertraline assignment were in lateral and posterior regions, aspects of default mode and association areas, namely temporal, parietal, and occipital regions. Perfusion in the temporal and occipital lobes have been observed, using positron emission tomography, to decrease from baseline to post-treatment in antidepressant responders [21]. A recent perfusion study identified regions in the inferior temporal and frontal gyri and anterior cingulate to normalise to that of healthy controls while on a SSRI for six weeks [15]. Our results indicate these regions can predict response to a SSRI. The opposite pattern observed for placebo, where the majority of the regions contributing to placebo assignment were in frontal regions, aspects of default mode and executive control networks, could be indicators of treatment sensitivity and a placebo effect to which other treatments may provide better response than sertraline, e.g., psychotherapy.

However, it must be noted that the highest contributors to sertraline or placebo assignment are part of the limbic system, i.e., putamen and insula (anterior for sertraline and posterior for placebo). Perfusion in the putamen has been observed 1) to be involved in reward processing [22], 2) to be higher in a group of depressed individuals relative to healthy controls [23], and 3) to reduce after a single dose of a SSRI in healthy controls (along with other serotonergic regions) [24]. As for the insula, this region 1) contains high concentrations of serotonin transporters [25], 2) is known to be involved in mood, salience, and affective processing [26,27], and 3) shows perfusion reduction upon SSRI.
within connectivity patterns functional connectivity moderators of treatment response revealed conditions [31,32]. Our parallel work in EMBARC investigating resting-state has been investigated and posited to underlie neuropsychiatric conditions. Disruption in large-scale networks that regulate information processing scale networks play a role in how patients may respond to treatment. – disruptions were moderators of placebo, mirroring our placebo contributors. Disruption -- especially in these functional networks. Interestingly, connectivity predicted better outcomes on sertraline. Multiple perfusion moderators within involved the cingulate. Increased pre-treatment anterior cingulate theta activity was observed to be a non-specific predictor of treatment response [34]. Perfusion in the anterior cingulate moderated outcome in our model, but contributed less to treatment assignment compared to other regions suggesting it may not be a strong moderator of outcome. 4.1. Limitations and Future Directions

Important next steps would be to 1) replicate perfusion moderators of treatment response by using perfusion moderators to assign sertraline prior to starting treatment; and 2) investigate the ability of perfusion to differentiate between two or more active MDD treatments of differing modalities. These highlight the main limitations of the EMBARC trial. EMBARC data provided a relatively homogenous MDD sample, early-onset, chronic primary MDD, which likely provided a stronger signal to detect predictors of response to sertraline, but may also limit the transfer of these moderators to more heterogeneous populations of MDD. Replication is needed to determine if moderators observed in the current study will translate to other MDD populations, whether relatively homogenous or more heterogeneous in nature. Despite symptom levels being equivalent between the groups (e.g., depression severity, anxiety, and anhedonia; see Table 1), the effect symptoms and even comorbid conditions might have on perfusion markers and their role as biosignatures is worth further investigation. EMBARC was also restricted to one active treatment (a SSRI), so inclusion of other depression treatment modalities such as SNRIs, psychotherapy and rTMS are warranted to understand the broader promise of using perfusion to predict response to treatment. Additional limitations include 1) residual site effects, and 2) overall response in the trial for sertraline did not outperform placebo. The current study did not investigate site effects beyond controlling for such effects through normalisation and analytic modelling. Other EMBARC work is focusing on such effects

**Table 2**

| Brain Region at Peak Voxel in Cluster (Additional Brain Regions in Cluster) | MNI Coordinates (x, y, z) | Brodmann Area (BA) | # of Voxels | Weight in Composite Moderator |
|---|---|---|---|---|
| **Sertraline Contributors** | | | | |
| Right Putamen (Stria Terminalis, Dorsal and Ventral Striatum) | 28, 12, 6 | 31, 47 | 331 | -0.23998 |
| Left Inferior Frontal Gyrus (Middle Temporal, Fusiform Gyri) | -48, -2, -34 | 20, 36 | 674 | -0.10646 |
| Right Fusiform (Right Inferior Temporal, Occipital Gyri) | 42, -56, -12 | 37, 19 | 422 | -0.10309 |
| Right Inferior/Orbital Frontal Gyrus (Anterior Insula) | 38, 32, 2 | 47 | 149 | -0.06916 |
| Left Parahippocampal Gyrus (Temporal Pole) | -18, -4, -31 | 35, 36, 38, 28 | 201 | -0.06545 |
| Left Inferior Parietal Lobule (Supramarginal Gyrus) | -60, -46, 42 | 40 | 282 | -0.05842 |
| Left Fusiform Gyrus (Cerebellum) | -38, -58, -16 | 37 | 667 | -0.0502 |
| Bilateral Pons | -0, -20, -32 | 156 | -0.0453 |
| Right Precuneus (Left Precuneus, Right Posterior Cingulate) | 4, -56, 36 | 7, 23, 31 | 547 | -0.03692 |
| Left Inferior Parietal Lobule (Supramarginal and Angular Gyri, Superior Parietal Lobule, Precuneus) | -36, -56, 56 | 40, 39, 7 | 339 | -0.02229 |
| Left Superior Temporal Gyrus | -46, -12, 2 | 48, 22 | 108 | -0.01324 |
| Left Superior Temporal Gyrus (Insula) | -54, 4, 0 | 38 | 237 | -0.0092 |
| Right Calcarine Cortex | 24, -64, 16 | 18, 17 | 126 | -0.00724 |
| **Placebo Contributors** | | | | |
| Right Posterior Insula (Rolandic Operculum) | 34, -24, 20 | 13, 40, 41 | 275 | -0.136269 |
| Left Midbrain (Red Nucleus, Substantia Nigra, Lingular and Parahippocampal Gyri) | -8, -28, -10 | 311 | -0.111396 |
| Right Hippocampus | 32, -18, -8 | 20 | 109 | -0.10846 |
| Right Inferior/Orbital Frontal Gyrus (Insula, Superior Temporal Gyrus) | 34, 22, -22 | 47, 38 | 206 | -0.07918 |
| Right Middle and Inferior Frontal Gyri (Dorsolateral Prefrontal Cortex, Precentral Gyri) | 28, 20, 36 | 9, 46, 44 | 592 | -0.074757 |
| Left Precentral Gyrus (Paracentral Lobule, Middle Cingulate) | -12, -28, 56 | 4 | 179 | -0.068112 |
| Left Inferior/Orbital Frontal Gyrus | -26, 32, -14 | 11, 47 | 202 | -0.06751 |
| Left Middle Temporal Gyrus | -60, -46, -2 | 21, 20 | 217 | -0.064334 |
| Right Caudate Body and Head (Thalamus) | 12, 12, 8 | 640 | -0.06096 |
| Left Cerebellum | -44, -78, -32 | 398 | -0.052917 |
| Right Middle, Superior, and Inferior Frontal Gyri (Dorsolateral and Frontopolar Prefrontal Cortices) | 22, 44, 22 | 10, 45, 46 | 578 | -0.05214 |
| Left Middle Frontal Gyrus (Dorsolateral Prefrontal Cortex) | -28, 18, 44 | 6, 8, 9 | 148 | -0.020626 |
| Right Middle Temporal Gyrus (Temporal Pole) | 66, -28, -14 | 20, 21 | 152 | -0.012107 |
| Left Cuneus | -4, -90, 24 | 18 | 114 | -0.008888 |
| Left Ventral and Dorsal Anterior Cingulate Cortices | -8, 12, 32 | 24, 32, 33, 10, 11 | 6,463 | -0.00676 |
| Left Fusiform Gyrus (Lingular Gyri, Cerebellum) | -26, -78, -18 | 18, 19 | 212 | -0.00225 |
| Left Inferior Frontal Gyrus (Triangularis) | -50, 18, 26 | 45 | 104 | -0.001889 |

Note. False Discovery Rate correction of p < .05 was implemented voxel-wise. Clusters presented are those greater than 100 voxels organized by contribution to treatment assignment (sertraline or placebo in composite moderator).
across the investigated modalities. EMBARC was not a drug efficacy trial, so while the failure to observe sertraline response to be greater than placebo is initially disconcerting, the current work shows that brain function can be used to improve treatment response when treatments perform equivalent otherwise.

Our findings show baseline cerebral blood perfusion, a quantitative measure of brain function, can predict treatment outcome and increase remission rates on sertraline in MDD. Emerging data such as these aid the field of psychiatry in classifying and treating MDD beyond just clinically-derived symptom profiles, but rather augmented or partially replaced by pathophysiology-derived diagnostic and prognostic markers of illness and clinical response [6,35].

Acknowledgements

The EMBARC study reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under award numbers U01MH092221 (Trivedi MH PI) and U01MH092250 (Weissman MM, McGrath P, Parsley R Ps). The work was also funded in part by the Hersh Foundation (Trivedi MH PI) and the Center for Depression Research and Clinical Care, Peter O’Donnell Brain Institute at UT Southwestern Medical Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was supported by the EMBARC National Coordinating Center at UT Southwestern Medical Center (Trivedi MH PI) and Data Center at Columbia University (Adams P PI). Peiying Liu provided assistance with the ASL processing pipeline. Thomas S. Harris provided assistance with ASL data processing.

Author Contributions

CC contributed to ASL collection, data processing, data analytic design, interpretation and wrote the manuscript; CCF contributed to data processing, conducting data analyses, and manuscript editing; MJ contributed to data analytic design, interpretation and manuscript editing; GF contributed to analytic design, analytic code, and manuscript editing; BG contributed to data analytic design and interpretation; TC contributed to data analytic design, conducting data analyses, and interpretation; AA contributed to ASL collection and manuscript editing; SA contributed to data processing and manuscript editing; JA contributed to ASL conceptualization on EMBARC and manuscript editing; TD coordinated data quality control centre, contributed to ASL quality control, and manuscript editing; MF is an EMBARC PI and contributed to EMBARC study design and manuscript editing; BK is an EMBARC PI and site investigator, and contributed to EMBARC study design and manuscript editing; PM is an EMBARC PI and site investigator, and contributed to EMBARC study design, ASL data analytic design, and manuscript editing; MM is a site investigator and contributed to manuscript editing; RP is an EMBARC PI, site investigator, coordinator of imaging data centre, and contributed to EMBARC study design and manuscript editing; MW is an EMBARC PI and contributed to EMBARC study design and manuscript editing; MP contributed to imaging study design, coordinating imaging processing centre, and manuscript editing; HL oversaw EMBARC ASL protocol, data processing pipeline and code, and manuscript editing; AE contributed to imaging study design, analytic design, interpretation, and manuscript editing; and MT is EMBARC’s Coordinating PI and contributed to EMBARC study design and rationale, and contributed to data analytic design, data interpretation, and manuscript editing.

Data Sharing Statement

EMBARC data is publicly available at https://ndar.nih.gov, study #2199. All data is deidentified. Data available include the study protocol, data dictionary, scalar versions of clinical, behavioural, and imaging modalities, as well as raw behavioural and imaging files.

Declarations of Interest

Crystal Cooper, Cherise Chin Fatt, Bruce Grannemann, Jorge Almeida, Aasia Ali, Melvin McInnis, Ramin Parsley, Sina Aslan, and Hanzhang Lu have no disclosures or potential conflicts of interest. Manish Jha has received contract research grants from Acadia Pharmaceuticals and Janssen Research & Development. Thilo Deckerbach’s research has been funded by NIH, NIMH, NARSAD, TSA, IOCDF, Tufts University, DBDAT, Otsuka Pharmaceuticals, Cogito, Inc. and Sunovian. He has received honoraria, consultation fees and/or royalties from the MGH Psychiatry Academy, BrainCells Inc., Clintara, LLC, Systems Research and Applications Corporation, Boston University, the Catalán Agency for Health Technology Assessment and Research, the National Association of Social Workers Massachusetts, the Massachusetts Medical Society, Tufts University, NIDA, NIMH, and Oxford University Press. He has also participated in research funded by DARPA, NIH, NIMH, NIA, AHRQ, PCORI, Janssen Pharmaceuticals, The Forest Research Institute, Shire Development Inc., Medtronic, Cyberonics, Northstar, Takeda and Alphagamma. Maurizio Fava has received research support from Abbott Laboratories; Acadia Pharmaceuticals; Alkermes, Inc.; American Cyanamid; Aspect Medical Systems; AstraZeneca; Avanir Pharmaceuticals; AXSOME Therapeutics; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx Biopharma; Cephalon; Cercore; Clintara, LLC; Covance; CoviQien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; FORUM Pharmaceuticals; Genomed Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Jansen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante; Methylation Sciences Inc.; National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Coordinating Center for Integrated Medicine (NiiCM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; NeuroRx; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates, Inc.; Pharmavet® LLC; PharmoRx Therapeutics; Photothera; Reckitt Benckiser; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute (SMRI); Synthelabo; Takeda Pharmaceuticals; Tal Medical; VistaGen); Wyeth-Ayerst Laboratories; he has served as advisor or consultant to Abbott Laboratories; Acadia; Affects Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Avanir Pharmaceuticals; AXSOME Therapeutics; Bayer AG; Best Practice Project Management, Inc.; Biogen; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx Biopharma; Cephalon, Inc.; Cercore; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dininpop Sumitomo Pharma Co. Inc.; Dow Pharmaceuticals, Inc.; Edgemont Pharmaceutical, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; Forum Pharmaceuticals; GenOmind, LLC; GlaxoSmithKline; Gruenthal GmbH; Indivior; i3 Innovus/Ingenix; Intracelular; Janssen Pharmaceutical; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSL Methylation Sciences, Inc.; Naurex, Inc.; Nestle Health Sciences; Neuralstem, Inc.; Neurorinics, Inc.; NextWave Pharmaceuticals; Novartis AG; Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Osmotica; Otsuka Pharmaceuticals; Pamlab, LLC.; Pfizer Inc.; PharmStar; Pharmavet® LLC; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; PPD; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.; RCT Logic,
LLC (formerly Clinical Trials Solutions, LLC); Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC; Sepcor Inc.; Servier Laboratories; Schering-Plough Corporation; Shenyx Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Taisho Pharmaceutical; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; Transform Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.; VistaGen; he has received speaking or publishing fees from Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Medex, LLC; MGHI Psychiatry Academy/Primedia; MGHI Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource Corp.; Wyeth-Ayerst Laboratories; he has equity holdings in Compellis and PsyBrain, Inc.; he has a patent for Sequential Parallel Comparison Design (SPCD), which are licensed by MGHI to Pharmaceutical Product Development, LLC (PPD); and patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder (MDD), licensed by MGHI to Biohaven; and he receives copyright royalties for the MGHI Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), Symptoms of Depression Questionnaire (SDQ), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte Ltd. Benji Kurian has received grant support from Targacept, Inc., Pfizer, Inc., Johnson & John-son, Evotec, Rexahn, Naurex, Forest Pharmaceuticals, and NimH.

Patrick McGrath has received funding from the National Institute of Mental Health, New York State Department of Mental Hygiene, Research Foundation for Mental Hygiene (New York State), Forest Research Laboratories, Sunovion Pharmaceuticals, and Naurex Pharmaceuticals (now Allergan). Myrna Weissman received funding from the National Institute of Mental Health (NIMH), the National Insti-tute on Drug Abuse (NIDA), the National Alliance for Research on Schizophrenia and Depression (NARSAD), the Sackler Foundation, and the Templeton Foundation; and receives royalties from the Oxford Uni-versity Press, Perseus Press, the American Psychiatric Association Press, and MultiHealth Systems. Mary Phillips received funding from the National Institute of Mental Health (NIMH). Amit Etkin has equity options in Mindstrong Health and Akili Interactive for unrelated work.

Madhukar Trivedi is or has been an advisor/consultant and received fee from (lifetime disclosure): Abbott Laboratories Inc., Akzo (Organon Pharmaceuticals Inc.), Allergan Sales LLC, Alkermes, Arcadia Pharma-ceuticals Inc., AstraZeneca, Axon Advisors, Brintellix, Bristol-Myers Squibb Company, Cephalon Inc., Cerecor, Eli Lilly & Company, Evotec, Fabre Kramer Pharmaceuticals Inc., Forest Pharmaceuticals, GlaxoSmithKline, Global Medical Education Inc., Health Research Asso-ciates, Johnson & Johnson, Lundbeck, MedAvante Medscape, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America Inc., MSI, Methyltion Sciences Inc., Nestle Health Science-PamLab Inc., Naurex, Neuronetics, One Carbon Therapeutics Ltd., Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals Inc., Pfizer Inc., PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepcor, SHIRE Development, Sierra, SK Life and Science, Sunovion, Takeda, Tai Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories. In addi-tion, he has received grants/research support from: Agency for Healthcare Research and Quality, Cyberonics Inc., National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Diabetes and Digestive and Kidney Diseases, Johnson & Johnson; and he receives royalties from Janssen Research and Development LLC.

Appendix A. Supplementary Data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.eclinm.2019.04.007.

References

[1] Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Balasubramani GK, McGrath PJ, et al. Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR-T D. J. Gen Intern Med 2008;23:51–60.
[2] Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008;455:894–902.
[3] Trivedi MH, McGrath PJ, Fava M, Parsey RV, Kuriyan BT, Phillips ML, et al. Establishing moderators and biomarkers of antidepressant response in clinical care (EMBARC), rationale and design. J Psychiatr Res 2016;78:11–23.
[4] Trivedi MH. Modeling predictors, moderators and mediators of treatment outcome and resistance in depression. Biol Psychiatry 2013;74:2–.
[5] Phillips MT, Chace HW, Sheline YI, Etkin A, Almeida JR, Deckersbach T, et al. Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am J Psychiatry 2015;172:124–38.
[6] Abi-Dargham A, Horga C. The search for imaging biomarkers in psychiatric disorders. Neuroimage 2015;106:111–22.
[7] Aslop DC, Detre JA, Golay X, Günther M, Hendriks J, Hernandez-Garcia L, et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ESMRMB perfusion study group and the European consortium for ASL in dementia. Magn Reson Med 2015;73:102–16.
[8] Jann K, Gek Dg, Klimo E, Schwab S, Smith RX, Cannon TD, et al. Functional connectivity in BOLD and CBF data: similarity and reliability of resting brain networks. Neuroimage 2015;106:111–22.
[9] Almeida JRC, Greenberg T, Lu H, Chase HW, Fournier JC, Cooper CM, et al. Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: findings from the EMBARC study. Magn Reson Imaging 2017;45:26–33.
[10] Chen G, Bian H, Jiang D, Cui M, J S, Lu M, et al. Pseudo-continuous arterial spin labeling of cerebral blood perfusion asymmetry in drug-naive patients with first-episode major depression. Biomed Rep 2016;5:675–80.
[11] Ota M, Noda T, Sato N, Hattori K, Teraishi T, Hori H, et al. Characteristic distributions of regional cerebral blood flow changes in major depressive disorder: patients with a pseudo-continuous arterial spin labeling (pCASL) study. J Affect Disord 2014;165:59–63.
[12] Lu S, Parkes LM, Huang X, Zou K, Khan RC, Yang H, et al. Depressive disorders: fo-cally altered cerebral perfusion measured with arterial spin-labeling MR imaging. Radiology 2009;251:476–84.
[13] Almeida JRC, Mourao-Miranda J, Aizenstein HJ, Versace A, Koelz FA, Sheline YI, et al. Pattern recognition analysis of anterior cingulate cortex blood flow to classify bipolar v. unipolar depression. Br J Psychiatry 2013;203:310–1.
[14] Weiduschat N, Dublin MJ. Prefrontal cortical blood flow predicts response of depres-sions. J Affect Disord 2013;150:699–702.
[15] Kauchi Y, Okada C, Takamura M, Toku S, Akiyama Y, Higaki T, et al. Changes in the regional cerebral blood flow detected by arterial spin labeling after 6-week escitalopram treatment for major depressive disorder. J Affect Disord 2016;194:135–43.
[16] Almeida JRC, Lu H. On the sensitivity of ASL for detecting regional differences in cere-bral blood flow. Magn Reson Imaging 2010;28:928–35.
[17] Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and moderators of treat-ment effects in randomized clinical trials. Arch Gen Psychiatry 2002;59:877–83.
[18] Kraemer HC. Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach. Stat Med 2013;32:1964–73.
[19] Petkova E, Ogden RT, Tarpey T, Clarlegio A, Jiang B, Su Z, et al. Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biomarkers of Antidepressant Response for Clinical Care) Study. Contemp Clin Trials Commun 2017;6:22–30.
[20] Kapelner A, Bleich J, Cohen ZD, DeRubeis RJ, Berk R. Inference for treatment regime models in personalized medicine. StatMed 2014;arXiv:1404.7844/1:1–31.
[21] Davies J, Lloyd K, Jones I, Barnes A, Pilowsky L. Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression. Am J Psychiatry 2003;160:374–6.
[22] Knobton B, Ii J, Conn, RE, Atias LY, Gotlib. Neural responses to monetary incen-tives in major depression. Biol Psychiatry 2008;63:886–902.
[23] Duhaumea B, Ferré JC, Jannin P, Gaurv JY, Vérin M, Mallet B, et al. Chronic and treatment-resistant depression: a study using arterial spin labeling perfusion MRI at 3Telsa. Psychiatry Res 2010;182:111–6.
[24] Chen Y, Wu H, O’Reardon JP, Wu DJ, Wang Z, Korczynski M, et al. Quantifica-tion of cerebral blood flow as biomarker of drug effect: arterial spin labeling pMRI after a single dose of oral citalopram. Clin Pharmacol Ther 2011;89:251–8.
[25] Vardas K, Hallidi C, Hall H. Autoradiographic distribution of serotonin transporters in human brain. Hum Brain Mapp 2004;22:246–60.
[26] Gu X, Hof PR, Friston KJ, Fan J. Anterior insular cortex and emotional awareness. J Comp Neurol 2013;523:3711–88.
[27] Menon V. Salience network. Brain mapping: an encyclopedic reference volume 2: 215–36.
[28] Mayberg HS, Liotti M, Shenton M, Krainik A, McGinnis S, Minshew NK, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999;156:675–82.
[29] Maia TV, Frank M. From reinforcement learning models to psychiatric and neurological disorders. Nat Neurosci 2011;14:154–62.

[30] Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003;65:193–207.

[31] Chen AC, Oathes D, Chang C, Bradley T, Zhou ZW, Williams LM, et al. Causal interactions between fronto-parietal central executive and default-mode networks in humans. Proc Natl Acad Sci U S A 2013;110:19944–9.

[32] McTeague LM, Huemer J, Carreon DM, Jiang Y, Eickhoff SB, Etkin A. Identification of common neural circuit disruptions in cognitive control across psychiatric disorders. Am J Psychiatry 2017;174:676–85.

[33] Chin Fatt CR, Cooper CM, Jha M, Fonzo G, South C, Grannemann B, Carmody T, Greer T, Kuriian B, Fava M, McGrath P, Adams P, McInnis M, Parsey R, Weissman M, Phillips M, Elkin A, Trivedi MH. Intrinsic patterns of functional connectivity moderate antidepressant treatment response in major depression. Am J Psychiatry. [Revised and Resubmitted].

[34] Pizzagalli DA, Webb CA, Dillon DG, Tenke CE, Kayser J, Goer F, et al. Pretreatment rostral anterior cingulate cortex theta activity in relation to symptom improvement in depression: a randomized clinical trial. JAMA Psychiat 2018;75:547–54.

[35] Charney DS, Barlow DH, Botteron KN, Cohen JD, Goldman D, Gur RC, et al. Neuroscience research agenda to guide development of a pathophysiologically based classification system. In: Kupfer DJ, First MB, Regier DA, editors. A research agenda for DSM-V. Washington, DC: American Psychiatric Association; 2002. p. 31–83.